Jiangxi Fushine Pharmaceutical Co Ltd

Jiangxi Fushine Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.77, indicating a moderate level of leverage. The company's liquidity is assessed as medium, with a current ratio of 1.15, suggesting it has just enough current assets to cover its current liabilities. However, the company's free cash flow is negative at -155.06 million CNY, and its operating cash flow is only 62.67 million CNY, which may limit its ability to fund operations and investments without external financing. Profitability metrics show a challenging financial position. The company reported a net loss of 55.03 million CNY and an operating loss of 66.09 million CNY. Return on equity is -2.52%, and return on assets is -1.25%, both significantly below industry norms. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. This lack of geographic diversification increases its exposure to domestic economic and regulatory risks. There are no disclosed segments beyond the core pharmaceutical business, and the company does not appear to have a diversified product portfolio. Looking ahead, the company's revenue is expected to remain under pressure. Analysts have estimated a mean EPS of 0.36 CNY for the current fiscal year, but the last actual EPS was -0.10 CNY, indicating a significant gap between expectations and performance. The company's capital expenditure of -224.88 million CNY suggests it is investing in its operations, but the negative free cash flow indicates that these investments are not yet generating positive returns. The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a low probability of dilution, but the company's net cash position is negative after subtracting total debt, which could necessitate additional financing. The company's liquidity risk is moderate, and its credit risk is not explicitly quantified, but the negative operating and net income suggest potential challenges in maintaining creditworthiness. Recent events and filings do not indicate any major corporate actions or strategic shifts. The company's financial performance has been volatile, with a net loss in the latest reported period. There are no recent transcripts or filings that suggest a significant change in strategy or operations. The company's stock has a mean recommendation of 1.00 from analysts, indicating a strong buy, but the actual performance has not met expectations.